BIALTEC SAS
- Founded in: 2012
- Number of employees: 9
- Country: Colombia
- Website: bialtec.co
Which input provides your business model/core technology towards a bio-based economy?
All the additives we produce are made by biotechnology (fermentations, enzymatic reactions and natural extractions) on the other hand we perform intestinal microbiota DNA sequences and inhibition tests to develop our formulations, we also develop a simulator of the gastrointestinal system that allows us to predict changes associated with diets, additives, pathogens, antibiotics and others. We want to understand the animal intestinal microbiota very well and from there create the best additives
Which market/clients do you address and which short-term/long-term goals do you have?
Composite feed manufacturers, pet food producers and feed additive producers, to put our additives in their formulations and assist in the reduction of antibiotic growth promoters. Our goal is to establish ourselves in Europe and continue designing the gastrointestinal system simulator with real data collected by DNA sequencing, to continue creating the next generation of animal growth promoters free of antibiotics
What makes your approach unique compared to other stakeholders in the field?
Microbiology: to quantify the reduction of pathogenic bacteria with the use of our feed additives. Special formulations that work Biotechnology: to scale production processes, such as probiotic cultures (sometimes isolated from farms), the production of prebiotics and phytobiotics Metagenomics: data helps us design better products and measure their impact, we also design performance simulations under certain conditions. Encapsulation: we have developed the highest protection against thermal and digestive processes for live strains used in our products, we can also protect phytobiotics and other temperature sensitive molecules.
You can meet BIALTEC SAS at EFIB in Brussels on 30 September – 2 October 2019.